Hypertriglyceridemia in young adults with a 22q11.2 microdeletion.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
19 May 2022
Historique:
received: 30 10 2021
accepted: 27 04 2022
pubmed: 7 5 2022
medline: 21 5 2022
entrez: 6 5 2022
Statut: epublish

Résumé

Mild to moderate hypertriglyceridemia is a condition often associated with obesity and diabetes, with as yet incomplete knowledge of underlying genetic architecture. The 22q11.2 microdeletion is associated with multimorbidity, including increased risk of obesity and diabetes. In this study, we sought to investigate whether the 22q11.2 microdeletion was associated with mild to moderate hypertriglyceridemia (1.7-10 mmol/L). This was a cohort study comparing 6793 population-based adults and 267 with a 22q11.2 microdeletion aged 17-69 years, excluding those with diabetes or on statins. We used binomial logistic regression modeling to identify predictors of hypertriglyceridemia, accounting for the 22q11.2 microdeletion, male sex, BMI, ethnicity, age, and antipsychotic medications. The 22q11.2 microdeletion was a significant independent predictor of mild to moderate hypertriglyceridemia (odds ratio (OR): 2.35, 95% CI: 1.70-3.26). All other factors examined were also significant predictors (OR: 1.23-2.10), except for antipsychotic medication use. Within the 22q11.2 microdeletion subgroup, only male sex (OR: 3.10, 95% CI: 1.77-5.44) and BMI (OR: 1.63, 95% CI: 1.14-1.98) were significant predictors of hypertriglyceridemia, evident at mean age 31.2 years. The 22q11.2 microdeletion is associated with hypertriglyceridemia even when accounting for other known risk factors for elevated triglycerides. This effect is seen in young adulthood (76.6% were <40 years), in the absence of diabetes, and irrespective of antipsychotics, suggesting that the 22q11.2 microdeletion may represent an unrecognized genetic risk factor for hypertriglyceridemia, providing novel opportunities for animal and cellular models. Early dyslipidemia screening and management strategies would appear prudent for individuals with 22q11.2 microdeletions.

Identifiants

pubmed: 35521712
doi: 10.1530/EJE-21-1104
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-99

Auteurs

Christina Blagojevic (C)

Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
The Dalglish Family 22q Clinic, University Health Network, Toronto, Ontario, Canada.

Tracy Heung (T)

Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
The Dalglish Family 22q Clinic, University Health Network, Toronto, Ontario, Canada.

Sarah Malecki (S)

Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
The Dalglish Family 22q Clinic, University Health Network, Toronto, Ontario, Canada.

Shengjie Ying (S)

Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
The Dalglish Family 22q Clinic, University Health Network, Toronto, Ontario, Canada.

Sabrina Cancelliere (S)

Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.

Robert A Hegele (RA)

Departments of Medicine and Biochemistry, Robarts Research Institute, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

Anne S Bassett (AS)

Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
The Dalglish Family 22q Clinic, University Health Network, Toronto, Ontario, Canada.
Department of Psychiatry, University of Toronto, Toronto General Hospital Research Institute, and Campbell Family Mental Health Research Institute, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH